Down-regulated miR-22 as predictive biomarkers for prognosis of epithelial ovarian cancer

Diagnostic Pathology

Volumn 9, Issue 1, 2014, Pages 1-6

  Wan, Wei na ^a   Zhang, Yu qin ^a   Wang, Xue mei ^a   Liu, Yan jun ^a   Zhang, Yi xia ^a   Que, Yan hong ^a   Zhao, Wen jing ^a   Li, Ping ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Biomarkers; Epithelial ovarian cancer; MiR 22; Prognosis

Indexed keywords

MICRORNA; MIRN22 MICRORNA, HUMAN; TUMOR MARKER;

CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY;

BIOMARKERS, TUMOR; CHI-SQUARE DISTRIBUTION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MICRORNAS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84908092413     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/s13000-014-0178-8     Document Type: Article

References (30)

1. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 2006, 20(2):207-225. 10.1016/j.bpobgyn.2005.10.007, 16359925.
2. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer 2000, 89(10):2068-2075. 10.1002/1097-0142(20001115)89:10<2068::AID-CNCR6>3.0.CO;2-Z, 11066047.
3. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000, 19(1):3-10. 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S, 10883018.
4. Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, Gardiman M, Rugge M, Gomella LG, Croce CM, Rosenberg A. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009, 219(2):214-221. 10.1002/path.2586, 19593777.
5. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs-the micro steering wheel of tumour metastases. Nat Rev Cancer 2009, 9(4):293-302. 10.1038/nrc2619, 19262572.
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297. 10.1016/S0092-8674(04)00045-5, 14744438.
7. Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 2005, 353(17):1768-1771. 10.1056/NEJMp058190, 16251533.
8. Wang W, Li F, Zhang Y, Tu Y, Yang Q, Gao X: Reduced expression of miR-22 in gastric cancer is related to clinicopathologic characteristics or patient prognosis. Diagn Pathol 2013, 8:102..
9. Zhang G, Xia S, Tian H, Liu Z, Zhou T. Clinical significance of miR-22 expression in patients with colorectal cancer. Med Oncol 2012, 29(5):3108-3112. 10.1007/s12032-012-0233-9, 22492279.
10. Zhang J, Yang Y, Yang T, Liu Y, Li A, Fu S, Wu M, Pan Z. Zhou W: microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer 2010, 103(8):1215-1220. 10.1038/sj.bjc.6605895, 20842113.
11. Xiong J, Yu D, Wei N, Fu H, Cai T, Huang Y, Wu C, Zheng X, Du Q, Lin D, Liang Z. An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples. FEBS J 2010, 277(7):1684-1694. 10.1111/j.1742-4658.2010.07594.x, 20180843.
12. Kawahigashi Y, Mishima T, Mizuguchi Y, Arima Y, Yokomuro S, Kanda T, Ishibashi O, Yoshida H, Tajiri T, Takizawa T. MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cell-specific microRNAs. J Nippon Med Sch 2009, 76(4):188-197. 10.1272/jnms.76.188, 19755794.
13. Lionetti M, Agnelli L, Mosca L, Fabris S, Andronache A, Todoerti K, Ronchetti D, Deliliers GL, Neri A. Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosomes Cancer 2009, 48(6):521-531. 10.1002/gcc.20660, 19306352.
14. Franchina T, Amodeo V, Bronte G, Savio G, Ricciardi GR, Picciotto M, Russo A, Giordano A, Adamo V. Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. J Cell Physiol 2014, 229(1):97-99. 23794259.
15. Rustin GJ, Timmers P, Nelstrop A, Shreeves G, Bentzen SM, Baron B, Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Eisenhauer E. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol 2006, 24(1):45-51. 10.1200/JCO.2005.01.2757, 16382112.
16. Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res 2005, 65(9):3509-3512. 10.1158/0008-5472.CAN-05-0298, 15867338.
17. Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 2006, 25(46):6188-6196. 10.1038/sj.onc.1209913, 17028598.
18. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6(4):259-269. 10.1038/nrc1840, 16557279.
19. Zhao J, Lu Q, Zhu J, Fu J, Chen YX: Prognostic value of miR-96 in patients with acute myeloid leukemia. Diagn Pathol 2014, 9:76..
20. Zhang R, Zheng S, Du Y, Wang Y, Zang W, Zhao G: Levels of HOXB7 and miR-337 in pancreatic ductal adenocarcinoma patients. Diagn Pathol 2014, 9:61..
21. Liu X, Yu H, Cai H, Wang Y: The expression and clinical significance of miR-132 in gastric cancer patients. Diagn Pathol 2014, 9:57..
22. Su ZX, Zhao J, Rong ZH, Geng WM, Wu YG, Qin CK: Upregulation of microRNA-25 associates with prognosis in hepatocellular carcinoma. Diagn Pathol 2014, 9:47..
23. Wu L, Li G, Feng D, Qin H, Gong L, Zhang J, Zhang Z: MicroRNA-21 expression is associated with overall survival in patients with glioma. Diagn Pathol 2013, 8:200..
24. Gurha P, Abreu-Goodger C, Wang T, Ramirez MO, Drumond AL, van Dongen S, Chen Y, Bartonicek N, Enright AJ, Lee B, Kelm RJ, Reddy AK, Taffet GE, Bradley A, Wehrens XH, Entman ML, Rodriguez A. Targeted deletion of microRNA-22 promotes stress-induced cardiac dilation and contractile dysfunction. Circulation 2012, 125(22):2751-2761. 10.1161/CIRCULATIONAHA.111.044354, 22570371.
25. Iliopoulos D, Malizos KN, Oikonomou P, Tsezou A: Integrative microRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory networks. PLoS One 2008, 3(11):e3740..
26. Ting Y, Medina DJ, Strair RK, Schaar DG. Differentiation-associated miR-22 represses Max expression and inhibits cell cycle progression. Biochem Biophys Res Commun 2010, 394(3):606-611. 10.1016/j.bbrc.2010.03.030, 20214878.
27. Yamakuchi M, Yagi S, Ito T, Lowenstein CJ: MicroRNA-22 regulates hypoxia signaling in colon cancer cells. PLoS One 2011, 6(5):e20291..
28. Ling B, Wang GX, Long G, Qiu JH, Hu ZL. Tumor suppressor miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3. J Cancer Res Clin Oncol 2012, 138(8):1355-1361. 10.1007/s00432-012-1194-2, 22484852.
29. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G, Rameh L, Loda M, Pandolfi PP: Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal 2010, 3(117):ra29..
30. Li J, Liang S, Yu H, Zhang J, Ma D, Lu X. An inhibitory effect of miR-22 on cell migration and invasion in ovarian cancer. Gynecol Oncol 2010, 119(3):543-548. 10.1016/j.ygyno.2010.08.034, 20869762.